Chart-Typ:
Zeitraum:
| Infosys Unveils AI First Value Framework: Uniquely Positioned to Capture New AI Services Opportunity of Over $300 Billion | BENGALURU, India, Feb. 17, 2026 /PRNewswire/ -- Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next generation digital services and consulting, today unveiled its AI first... ► Artikel lesen |
| Infosys and Anthropic Announce Collaboration to Unlock AI Value across Complex, Regulated Industries | Collaboration launches in telecommunications with dedicated Anthropic Center of Excellence, expanding across financial services, manufacturing, and software developmentInfosys Topaz and Anthropic's... ► Artikel lesen |
| Infosys and Tennis Australia Bring AI-First Experiences and Accessibility to Australian Open 2026 | Enhancing fan engagement with insights, accessibility, and responsible innovationShowcasing Rally, an interactive AI mascot, and MatchFeel, a tactile experience for visually impaired audiencesMELBOURNE... ► Artikel lesen |
| ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally | 2025 Sales Momentum: ANKTIVA net product revenue increased 20% quarter-over-quarter, with full-year net product revenue of $113 million, representing an approximately 700% increase year-over-year... ► Artikel lesen |
| ImmunityBio, Inc.: ImmunityBio Expands Access to ANKTIVA in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch |
ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countries
Dublin-based subsidiary to support ImmunityBio's distribution... ► Artikel lesen |
| ImmunityBio, Inc.: ImmunityBio Receives Authorization from the European Commission for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries |
ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ... ► Artikel lesen |
| Energous Reports Preliminary Financial Results for Fiscal Year 2025, Marking a Transformational Year of Growth and Platform Expansion | Energous reports preliminary revenue of approximately $5.6 million for the year ended December 31, 2025, representing more than 630% year-over-year growth and record annual revenue.For the quarter... ► Artikel lesen |
| Energous Reports Further Increase in Quarterly Revenue, Driven by Accelerating Adoption of Wireless Power Networks | Successive Revenue Growth: Reports preliminary quarterly revenue of approximately $1.3 million for the three months ended September 30, 2025 - the highest quarterly revenue since 2015 - with operational... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SS INNOVATIONS INTERNATIONAL INC finden Sie auf Wallstreet Online.